Litcius/Paper detail

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress

Shun Lü, Ignacio Casarini, Terufumi Kato, Manuel Cobo, Mustafa Özgüroğlu, Rachel Hodge, Toon van der Gronde, Matilde Saggese, Suresh S. Ramalingam

2021Clinical Lung Cancer63 citationsDOI

Topics & Concepts

MedicineOsimertinibInternal medicineLung cancerOncologyProgression-free survivalT790MAdverse effectResponse Evaluation Criteria in Solid TumorsClinical endpointClinical trialCancerPhases of clinical researchEpidermal growth factor receptorErlotinibGefitinibChemotherapyLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress | Litcius